Japanese encephalitis (JE)
Japanese encephalitis (JE), the leading cause of viral encephalitis in Asia, causes an estimated 30,000 to 50,000 cases and 10,000 to 15,000 deaths each year, mostly among children under 15 years of age. There is no specific treatment for JE. Vaccination is the single most important measure for controlling the disease.
JE resources on the Vaccine Resource Library were mainly gathered during PATH’s JE project, which conducted technical activities from 2003 to 2009 in collaboration with local, regional, and global health stakeholders. For additional resources, visit the JE page on the World Health Organization website.
Safety and Immunogenicity of Concomitant Vaccination With the Cell-Culture Based Japanese Encephalitis Vaccine IC51 and the Hepatitis A Vaccine HAVRIX1440 in Healthy Subjects: A Single-Blind, Randomized, Controlled Phase 3 Study (2009)
An article about a study on the immunogenicity and safety of a JE vaccine and hepatitis A vaccine administered alone or concomitantly.
Epidemiology and Burden of Disease from Japanese Encephalitis in Cambodia: Results From Two Years of Sentinel Surveillance (2009)
An article about the results of two years of surveillance of JE disease in Cambodian children.
Featured PATH resources
Advocacy for Japanese Encephalitis (2009)
A fact sheet that summarizes PATH's efforts toward raising awareness about JE vaccination.
Japanese Encephalitis—Questions and Answers
A web page that provides answers to some of the most common questions about JE, including how to prevent JE through vaccination.
Page last updated: October 2013.